Analyst Consensus ?
ConsensusHold26 ratings
Bullish1350.0%
Neutral1246.2%
Bearish13.8%
1 unmapped firm rating excluded from the percentages.
The Cooper Companies, Inc. · COO · FY2024 Q2 · Calendar Q2 2024
Cooper Companies Raises FY2024 Guidance Despite Distribution Disruption
The current quarter supports a constructive but conditional view: resilient demand across daily lenses, myopia management and fertility products, together with capacity expansion, is supporting growth and guidance. The evidence still needs to show that this momentum can persist through tougher comparisons, channel inventory changes and the temporary distribution disruption.
Reported After market closeNASDAQHealthcare
$11.64B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$0.85
Consensus $0.83
EPS surprise
+2.5%
Reported versus consensus
Reported revenue
$942.6M
Consensus $948.1M
Revenue surprise
-0.6%
Reported versus consensus
Market reaction
event-close to next-session close
Stock move
+4.5%
Event window
SPY move
+0.9%
Same window
Abnormal move
+3.6%
Stock minus SPY
Volume
3.7×
Versus trailing sessions
Subsequent drift
-8.4%
Up to 20 sessions
COOSPY benchmark
Ask FN2 about COO FY2024 Q2
Transcript, numbers and history already loaded
Why did COO rise 4.5% after beating EPS estimates in FY2024 Q2?What changed in COO's guidance and outlook in FY2024 Q2?Give me the bull and bear case for COO after FY2024 Q2 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior quarter, Cooper Companies again reported record revenue and raised full-year guidance, while the key new operating issue was a temporary US distribution-center system upgrade that delayed shipments. Management also emphasized capacity expansion, additional product launches and broader myopia-management and fertility initiatives.
Guidance delta
Management raised full-year revenue guidance to $3.86-$3.90 billion and non-GAAP EPS guidance to $3.54-$3.60.
Key takeaways
- Q2 revenue reached a record $943 million, up 8% year over year, with CooperVision delivering 11% organic growth.
- Management cited strong demand for daily silicone hydrogel lenses, MiSight, fertility products and premium contact-lens categories.
- A US distribution-center system upgrade temporarily delayed shipments; management said the backlog was being cleared.
- Capacity expansion and new product launches remain central to supporting growth.
Management priorities
- Ramp production on new manufacturing lines for MyDay and other daily lenses.
- Launch Energys lenses in additional markets and expand myopia-management initiatives.
- Expand fertility donor sites and training centers while continuing organic research and development.
Follow COO with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$61.21Current
$59Low
$92.69Average
$368High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 25, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Needham | Buy | Buy | Maintain | Sep 15, 2026 |
| Mizuho | Outperform | Outperform | Maintain | Sep 11, 2026 |
| William Blair | Market Perform | Outperform | Downgrade | Sep 10, 2026 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Sep 10, 2026 |
| UBS | Neutral | Neutral | Maintain | Sep 10, 2026 |
| Stifel | Buy | Buy | Maintain | Sep 10, 2026 |
| Piper Sandler | Neutral | Overweight | Downgrade | Sep 10, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | Sep 10, 2026 |
| Citigroup | Neutral | Neutral | Maintain | Sep 10, 2026 |
| Baird | Neutral | Outperform | Downgrade | Sep 10, 2026 |
| B of A Securities | Neutral | Buy | Downgrade | Sep 10, 2026 |
| BNP Paribas | Outperform | Outperform | Maintain | Jun 8, 2026 |
| Barclays | Overweight | Overweight | Maintain | Mar 6, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Dec 8, 2025 |
| Goldman Sachs | Sell | Sell | Maintain | Dec 8, 2025 |
| Redburn Atlantic | Neutral | Buy | Downgrade | Oct 4, 2023 |
| Jefferies | Hold | Buy | Downgrade | Oct 11, 2022 |
| Keybanc | Overweight | Downgrade | Aug 28, 2022 | |
| Stephens & Co. | Overweight | Overweight | Maintain | Jun 2, 2022 |
| Guggenheim | Buy | Neutral | Upgrade | Jan 2, 2022 |
| Raymond James | Outperform | Outperform | Maintain | Mar 4, 2021 |
| Oppenheimer | Perform | Perform | Maintain | Sep 3, 2020 |
| BMO Capital | Outperform | Outperform | Maintain | Mar 5, 2019 |
| Cleveland Research | Buy | Neutral | Upgrade | May 15, 2016 |
| PiperJaffray | Overweight | Overweight | Maintain | Dec 4, 2015 |
| Stifel Nicolaus | Buy | Buy | Maintain | Dec 1, 2015 |
| Morgan Keegan | Outperform | Outperform | Maintain | Mar 8, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $61.21. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Barclays | Analyst unavailable | $60 | $56.43 | -2.0% | Oct 6, 2026 |
| Mizuho Securities | Anthony Petrone | $75 | $55.22 | +22.5% | Sep 10, 2026 |
| UBS | Analyst unavailable | $66 | $63.48 | +7.8% | Sep 10, 2026 |
| Needham | David Saxon | $73 | $63.48 | +19.3% | Sep 10, 2026 |
| Wells Fargo | Analyst unavailable | $61 | $63.48 | -0.3% | Sep 10, 2026 |
| Stifel Nicolaus | Jonathan Block | $70 | $63.48 | +14.4% | Sep 10, 2026 |
| Robert W. Baird | Jeff Johnson | $61 | $63.48 | -0.3% | Sep 10, 2026 |
| Piper Sandler | Jason Bednar | $59 | $63.48 | -3.6% | Sep 10, 2026 |
| Needham | David Saxon | $86 | $62.02 | +40.5% | Jun 5, 2026 |
| Wells Fargo | Larry Biegelsen | $66 | $62.02 | +7.8% | Jun 5, 2026 |
| Mizuho Securities | Anthony Petrone | $85 | $60.34 | +38.9% | Jun 4, 2026 |
| Piper Sandler | Analyst unavailable | $86 | $61.21 | +40.5% | Jun 1, 2026 |
| Goldman Sachs | Analyst unavailable | $61 | $62.03 | -0.3% | May 27, 2026 |
| Needham | Analyst unavailable | $99 | $80.65 | +61.7% | Feb 3, 2026 |
| Barclays | Analyst unavailable | $98 | $81.29 | +60.1% | Jan 26, 2026 |
| Goldman Sachs | Analyst unavailable | $73 | $83.13 | +19.3% | Jan 9, 2026 |
| Goldman Sachs | Analyst unavailable | $71 | $81.4 | +16.0% | Dec 8, 2025 |
| Barclays | Matt Miksic | $91 | $81.4 | +48.7% | Dec 8, 2025 |
| Robert W. Baird | Analyst unavailable | $98 | $77.03 | +60.1% | Dec 5, 2025 |
| Mizuho Securities | Analyst unavailable | $100 | $77.03 | +63.4% | Dec 5, 2025 |
| Stifel Nicolaus | Jonathan Block | $95 | $77.03 | +55.2% | Dec 5, 2025 |
| Piper Sandler | Analyst unavailable | $94 | $77.03 | +53.6% | Dec 5, 2025 |
| Needham | David Saxon | $100 | $77.03 | +63.4% | Dec 5, 2025 |
| Barclays | Matt Miksic | $85 | $68.37 | +38.9% | Oct 13, 2025 |
| Goldman Sachs | David Roman | $64 | $68.56 | +4.6% | Oct 1, 2025 |
| Robert W. Baird | Jeff Johnson | $85 | $66.18 | +38.9% | Aug 28, 2025 |
| Morgan Stanley | Patrick Wood | $76 | $64.77 | +24.2% | Aug 28, 2025 |
| Stifel Nicolaus | Analyst unavailable | $85 | $64.58 | +38.9% | Aug 28, 2025 |
| Needham | David Saxon | $94 | $69.55 | +53.6% | Jun 17, 2025 |
| Stifel Nicolaus | Analyst unavailable | $105 | $85 | +71.5% | Mar 7, 2025 |
| Robert W. Baird | Analyst unavailable | $107 | $85 | +74.8% | Mar 7, 2025 |
| Jefferies | Young Li | $115 | $90.14 | +87.9% | Jul 16, 2024 |
| Piper Sandler | Jason Bednar | $115 | $90.23 | +87.9% | May 31, 2024 |
| Robert W. Baird | Jeff Johnson | $118 | $90.23 | +92.8% | May 31, 2024 |
| Mizuho Securities | Anthony Petrone | $110 | $93.34 | +79.7% | Aug 28, 2023 |
| Piper Sandler | Analyst unavailable | $375 | $351.02 | +512.6% | Jan 11, 2023 |
| Citigroup | Analyst unavailable | $368 | $315.67 | +501.2% | Dec 12, 2022 |
| Robert W. Baird | Jeff Johnson | $375 | $311.32 | +512.6% | Aug 24, 2022 |
| Stifel Nicolaus | Jonathan Block | $450 | $316.79 | +635.2% | Jun 14, 2022 |
| Wells Fargo | Larry Biegelsen | $480 | $442.01 | +684.2% | Aug 19, 2021 |
| Jefferies | Raj Denhoy | $112.5 | $98.61 | +83.8% | May 24, 2021 |
Track every rating change on COO the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationThe Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses. Their product range includes spherical lenses for common vision issues like nearsightedness and farsightedness, as well as advanced lenses such as toric for astigmatism, multifocal for presbyopia, and specialized options addressing myopia, dry eyes, and eye fatigue.…
Historical context
All COO earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| RDY Dr. Reddy's Laboratories Limited | FY2027 Q2 · Calendar Q4 2026 | +24.0% | -0.2% | Dr. Reddy’s: margins improve as semaglutide rollout advances |
| DGX Quest Diagnostics Incorporated | FY2026 Q3 · Calendar Q4 2026 | +4.5% | +1.8% | Quest Diagnostics: growth broadens, but PAMA remains a headwind |
| ARGX argenx SE | FY2026 Q3 · Calendar Q4 2026 | — | -1.6% | argenx: VYVGART momentum and a broader late-stage pipeline |
| MEDP Medpace Holdings, Inc. | FY2026 Q3 · Calendar Q4 2026 | +9.0% | -1.3% | Medpace: Record awards lift backlog as 2026 outlook improves |
| MOH Molina Healthcare, Inc. | FY2026 Q3 · Calendar Q4 2026 | +12.7% | +0.8% | Molina reaffirms 2026 outlook as Florida contract scales |
Latest beats and misses
Who reports nextBeat on EPS
- FCNCAFY2026 Q3 · October 23, 2026+19.9% EPS+8.2% move
- FCNCNFY2026 Q3 · October 23, 2026+19.9% EPS+0.2% move
- FCNCOFY2026 Q3 · October 23, 2026+19.9% EPS+1.0% move
- FCNCPFY2026 Q3 · October 23, 2026+19.9% EPS+1.0% move
- RDYFY2027 Q2 · October 23, 2026+24.0% EPS-0.2% move
- SLBFY2026 Q3 · October 23, 2026+3.7% EPS+7.1% move
Missed on EPS
- INFYFY2027 Q2 · October 23, 2026-4.8% EPS-6.6% move
- BBDFY2026 Q3 · October 22, 2026-7.7% EPS+3.0% move
- SNAFY2026 Q3 · October 22, 2026-5.9% EPS-3.4% move
- SPOTFY2026 Q3 · October 22, 2026-11.6% EPS+11.1% move
- VRSNFY2026 Q3 · October 22, 2026-2.0% EPS-0.9% move
- HBANMFY2026 Q3 · October 22, 2026-5.3% EPS+0.5% move
Get the COO recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2024-11-11T06:39:45.180704+00:00
- Polygon adjusted daily market bars · 2026-10-25T12:20:43.749178+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-25T12:20:43.746391+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-25. For educational purposes only; not investment advice.